153 related articles for article (PubMed ID: 24690325)
1. Outcome after intensity modulated radiotherapy for anaplastic thyroid carcinoma.
He X; Li D; Hu C; Wang Z; Ying H; Wu Y
BMC Cancer; 2014 Apr; 14():235. PubMed ID: 24690325
[TBL] [Abstract][Full Text] [Related]
2. Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma.
Xue F; Li D; Hu C; Wang Z; He X; Wu Y
Oncotarget; 2017 Feb; 8(9):15934-15942. PubMed ID: 27776342
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
Fan D; Ma J; Bell AC; Groen AH; Olsen KS; Lok BH; Leeman JE; Anderson E; Riaz N; McBride S; Ganly I; Shaha AR; Sherman EJ; Tsai CJ; Kang JJ; Lee NY
Cancer; 2020 Jan; 126(2):444-452. PubMed ID: 31593317
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in radiotherapy of anaplastic thyroid carcinoma: a single center study over 31 years.
Jacob J; Vordermark D; Lorenz K; Medenwald D
Radiat Oncol; 2023 Apr; 18(1):71. PubMed ID: 37076888
[TBL] [Abstract][Full Text] [Related]
5. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.
Foote RL; Molina JR; Kasperbauer JL; Lloyd RV; McIver B; Morris JC; Grant CS; Thompson GB; Richards ML; Hay ID; Smallridge RC; Bible KC
Thyroid; 2011 Jan; 21(1):25-30. PubMed ID: 21162687
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and Patterns of Recurrence for Anaplastic Thyroid Cancer Treated With Comprehensive Chemoradiotherapy.
Gao RW; Foote RL; Garces YI; Ma DJ; Neben-Wittich M; Routman DM; Patel SH; Ko SJ; McGee LA; Bible KC; Chintakuntlawar AV; Ryder M; Morris JC; Van Abel KM; Rivera M; Abraha F; Lester SC
Pract Radiat Oncol; 2022; 12(2):113-119. PubMed ID: 34715395
[TBL] [Abstract][Full Text] [Related]
7. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS
Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience.
Sultanem K; Shu HK; Xia P; Akazawa C; Quivey JM; Verhey LJ; Fu KK
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):711-22. PubMed ID: 11020568
[TBL] [Abstract][Full Text] [Related]
10. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.
Villeneuve H; Després P; Fortin B; Filion E; Donath D; Soulières D; Guertin L; Ayad T; Christopoulos A; Nguyen-Tan PF
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1866-71. PubMed ID: 21497452
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
Chintakuntlawar AV; Yin J; Foote RL; Kasperbauer JL; Rivera M; Asmus E; Garces NI; Janus JR; Liu M; Ma DJ; Moore EJ; Morris JC; Neben-Wittich M; Price DL; Price KA; Ryder M; Van Abel KM; Hilger C; Samb E; Bible KC
Thyroid; 2019 Nov; 29(11):1615-1622. PubMed ID: 31595822
[No Abstract] [Full Text] [Related]
12. [Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma].
Yu Z; Luo W; Zhou QC; Zhang QH; Kang DH; Liu MZ
Ai Zheng; 2009 Nov; 28(11):1132-7. PubMed ID: 19895731
[TBL] [Abstract][Full Text] [Related]
13. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
[TBL] [Abstract][Full Text] [Related]
15. Tumor Regression and Patterns of Distant Metastasis of T1-T2 Nasopharyngeal Carcinoma with Intensity-Modulated Radiotherapy.
Wu MY; He XY; Hu CS
PLoS One; 2016; 11(4):e0154501. PubMed ID: 27119991
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy.
Bhatia A; Rao A; Ang KK; Garden AS; Morrison WH; Rosenthal DI; Evans DB; Clayman G; Sherman SI; Schwartz DL
Head Neck; 2010 Jul; 32(7):829-36. PubMed ID: 19885924
[TBL] [Abstract][Full Text] [Related]
17. Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma.
Nachalon Y; Stern-Shavit S; Bachar G; Shvero J; Limon D; Popovtzer A
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1128-32. PubMed ID: 26512447
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience.
Lee N; Xia P; Quivey JM; Sultanem K; Poon I; Akazawa C; Akazawa P; Weinberg V; Fu KK
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):12-22. PubMed ID: 12007936
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.
Sugitani I; Miyauchi A; Sugino K; Okamoto T; Yoshida A; Suzuki S
World J Surg; 2012 Jun; 36(6):1247-54. PubMed ID: 22311136
[TBL] [Abstract][Full Text] [Related]
20. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
[Next] [New Search]
